Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.56 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.56 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.56 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.56 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.56 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1237406 | 0.88 | GRIA1 (0.56) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL17599033 | 0.82 | GRIA1 (0.56) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL7979916 | 0.82 | GRIK1 (0.56) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL29126949 | 0.80 | GRIK1 (0.50) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL30657602 | 0.80 | GRIK1 (0.50) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL10680326 | 0.80 | GRIA1 (0.67) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL31144760 | 0.79 | IDO1 (0.44) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL31053814 | 0.79 | GRIK1 (0.52) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL990709 | 0.78 | GRIA1 (0.54) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL19036228 | 0.77 | IDO1 (0.46) | MAPTCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | SYK, KDR, FLT1 | GRIA1 1412/4885GRIA2 1227/4885GRIA3 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.